UPDATE: Canaccord Genuity Decreases PT on Delcath Systems to $5
According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems (NASDAQ: DCTH) from $8 to $5.
Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).”
Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.
Latest Ratings for DCTH
|Mar 2016||WallachBeth||Initiates Coverage on||Buy|
|May 2013||Cowen & Co.||Downgrades||Outperform||Underperform|
|May 2013||Roth Capital||Downgrades||Buy||Sell|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.